CD44 and its implication in neoplastic diseases
MedComm · 2024-06 · 5 (6)
DOI: 10.1002/mco2.554 ↗At a glance
Übersichtsarbeit in MedComm, published online on 2024-05-23. Written by Yiming Xu and 4 co-authors. Institution: Department of Biotherapy Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center f…. Cited 39 times so far (Crossref); 296 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
CD44, a nonkinase single span transmembrane glycoprotein, is a major cell surface receptor for many other extracellular matrix components as well as classic markers of cancer stem cells and immune cells. Through alternative splicing of CD44 gene, CD44 is divided into two isoforms, the standard isoform of CD44 (CD44s) and the variant isoform of CD44 (CD44v). Different isoforms of CD44 participate in regulating various signaling pathways, modulating cancer proliferation, invasion, metastasis, and drug resistance, with its aberrant expression and dysregulation contributing to tumor initiation and progression. However, CD44s and CD44v play overlapping or contradictory roles in tumor initiation and progression, which is not fully understood. Herein, we discuss the present understanding of the functional and structural roles of CD44 in the pathogenic mechanism of multiple cancers. The regulation functions of CD44 in cancers‐associated signaling pathways is summarized. Moreover, we provide an overview of the anticancer therapeutic strategies that targeting CD44 and preclinical and clinical trials evaluating the pharmacokinetics, efficacy, and drug‐related toxicity about CD44‐targeted therapies. This review provides up‐to‐date information about the roles of CD44 in neoplastic diseases, which may open new perspectives in the field of cancer treatment through targeting CD44.
Subjects
Author keywords
Authors and institutions
- Department of Biotherapy Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Chengdu Sichuan…
- Laboratory of Aging and Geriatric Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Chengdu Sichuan China.
- Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu China.
Cite
APA
Xu, Y., Bai, Z., Lan, T., Fu, C., & Cheng, P. (2024). CD44 and its implication in neoplastic diseases. MedComm, 5(6). https://doi.org/10.1002/mco2.554
Vancouver
Xu Y, Bai Z, Lan T, Fu C, Cheng P. CD44 and its implication in neoplastic diseases. MedComm. 2024;5(6). doi:10.1002/mco2.554
BibTeX
@article{Xu2024,
author = {Xu, Yiming and Bai, Ziyi and Lan, Tianxia and Fu, Chenying and Cheng, Ping},
title = {CD44 and its implication in neoplastic diseases},
journal = {MedComm},
year = {2024},
volume = {5},
number = {6},
doi = {10.1002/mco2.554}
}
EUVIMED